Valproate

Edison issues initiation on Cereno Scientific (CRNO B): Differentiated approach in CVD with potential

Retrieved on: 
Wednesday, March 13, 2024

Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches.

Key Points: 
  • Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches.
  • Lead asset CS1, a delayed immediate release formulation of valproic acid, is an HDAC inhibitor, aiming to deliver disease-modifying results in pulmonary arterial hypertension (PAH).
  • Preclinical candidates include CS014, for thrombosis prevention without increased risk of bleeding (seen with current antithrombotics), and CS585 for CVD (specific indication not yet determined).
  • As with all Edison publications, Edison controls the editorial and timings of publications and we wish to make it clear that Cereno Scientific had no involvement in the aforementioned issue.

Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe

Retrieved on: 
Wednesday, August 30, 2023

OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).

Key Points: 
  • OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).
  • Acer and Relief have now agreed to terminate the CLA, where Acer is no longer required to pay Relief 60% of OLPRUVA™ net profits in the Acer territories and have regained all development and commercialization rights in rest of the world, excluding the Geographical Europe.
  • Additionally, Acer and Relief have entered into a new Exclusive License Agreement (ELA) in which Relief will retain development and commercialization rights for OLPRUVA™ in the Geographical Europe, where Acer will have the right to receive a royalty of up to 10% of the net sales of OLPRUVA™.
  • For additional Important Safety Information, see full Prescribing Information , Patient Package Insert and discuss with your doctor.

Deep Breath Intelligence Teams with HTEC Group and Effectum Medical to Accelerate the Launch of CE-marked device under IVDD

Retrieved on: 
Thursday, May 25, 2023

DBI-EPIbreath® is a unique easy-to-apply breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication valproic acid to aid patient management.

Key Points: 
  • DBI-EPIbreath® is a unique easy-to-apply breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication valproic acid to aid patient management.
  • Considering a very strict regulatory deadline that Deep Breath Intelligence had to meet to make DBI-EPIbreath® compliant, they approached HTEC to help them speed up their product launch considering regulatory requirements of IVDD in conjunction with Effectum Medical AG, the official legal manufacturer of the medical device.
  • "Every medical venture or initiative would like a speedy launch, but only the right skill set and partnership with a client can deliver.
  • Karina Candrian, CEO of Effectum Medical, said: "The project with DBI and HTECH is a great proof of our vision, 'We make innovation happen!'

Childhood Absence Epilepsy Treatment Market Report 2022-2027: High Prevalence of Epilepsy in Children and Rising Funding from Contract Research Organizations Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Key Points: 
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • It provides the idea of its revenue generation into the overall market compared to other vendors in the space.
  • Knowing market share offers an idea of the size and competitiveness of the vendors for the base year.
  • The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors.

Global Bipolar Disorder Therapeutics Market to 2026 - Featuring AbbVie, Astellas Pharma and Gedeon Richter Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 3, 2022

The "Bipolar Disorder Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bipolar Disorder Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Bipolar Disorder Therapeutics estimated at US$5.6 Billion in the year 2020, is projected to reach a revised size of US$6.8 Billion by 2026, growing at a CAGR of 3.1% over the analysis period.
  • This segment currently accounts for a 21.8% share of the global Bipolar Disorder Therapeutics market.
  • Anticonvulsant drugs aid in the treatment of bipolar disorder and in managing the mania associated with bipolar disorder.

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Retrieved on: 
Tuesday, October 19, 2021

The Joint Venture ("NewCo") will accelerate the research and development of psilocybin-based therapeutics by utilizing Mycrodose Therapeutics' patented advanced drug delivery systems with Nova's proprietary psilocybin drug to treat patients with neuroinflammatory conditions, including FXS, the most common inherited cause of ASD.

Key Points: 
  • The Joint Venture ("NewCo") will accelerate the research and development of psilocybin-based therapeutics by utilizing Mycrodose Therapeutics' patented advanced drug delivery systems with Nova's proprietary psilocybin drug to treat patients with neuroinflammatory conditions, including FXS, the most common inherited cause of ASD.
  • This collaboration with Mycrodose Therapeutics is a 'hand and glove fit' with our breakthrough psilocybin microdose discovery, as their advanced drug delivery technologies offer many advantages for microdosing drug delivery, including providing a non-invasive, sustained and controlled dose of medicine that can be self-administered."
  • NOVA has already successfully completed four preclinical studies confirming the therapeutic efficacy of the company's proprietary psilocybin drug.
  • Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases.

Insights on the Communication, Navigation & Surveillance Systems Global Market to 2026 - Featuring Garmin, GE Aviation and Honeywell International Among Others

Retrieved on: 
Monday, September 13, 2021

What are the inhibiting factors and impact of COVID-19 shaping the Global Communication, Navigation & Surveillance Systems Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Communication, Navigation & Surveillance Systems Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Communication, Navigation & Surveillance Systems Market?
  • What is the market share of the leading vendors in the Global Communication, Navigation & Surveillance Systems Market?
  • What modes and strategic moves are considered suitable for entering the Global Communication, Navigation & Surveillance Systems Market?

Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021

Retrieved on: 
Monday, February 22, 2021

XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders.

Key Points: 
  • XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders.
  • This work suggests that XEN1101 may be well suited for use as a monotherapy or applied in a rational polypharmacy setting to treat seizures.
  • Data were presented combining XEN1101 with commercially approved ASMs, including lacosamide, levetiracetam, cenobamate, phenytoin, and valproic acid.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint

Retrieved on: 
Monday, September 30, 2019

The global, multicenter, randomized, non-inferiority trial investigated the efficacy and safety of Mercks antibacterial product RECARBRIO for use in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

Key Points: 
  • The global, multicenter, randomized, non-inferiority trial investigated the efficacy and safety of Mercks antibacterial product RECARBRIO for use in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
  • By evaluating RECARBRIO in this patient population, we have generated robust clinical evidence for its potential use in patients with hospital-acquired and ventilator-associated bacterial pneumonia.
  • RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity (severe systemic allergic reaction such as anaphylaxis) to any component of RECARBRIO.
  • Concominant use of RECARBRIO with valproic acid or divalproex sodium may increase the risk of breakthrough seizures.